Sarcopenic Obesity and its Prognostic Impact on Urological Cancers: A Systematic Review
| Autor: | Harun Fajkovic, S.F. Shariat, Ganesh S. Palapattu, Simpa S. Salami, L. Y. Lai, Alan M. Zaslavsky, Randy Vince, J. Stangl-Kremser, Andrea Mari, Cheryl T. Lee |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Sarcopenia Urologic Neoplasms medicine.medical_specialty Adverse outcomes Urology Comorbidity Muscle mass Risk Assessment Risk Factors Internal medicine Prevalence medicine Humans Sarcopenic obesity Obesity business.industry Cancer Prognosis medicine.disease Progression-Free Survival Urological cancers Body Composition business |
| Zdroj: | Journal of Urology. 206:854-865 |
| ISSN: | 1527-3792 0022-5347 |
| DOI: | 10.1097/ju.0000000000001873 |
| Popis: | Sarcopenia, an age-related loss of muscle mass and function, may predict adverse outcomes for patients with urological cancers. However, the clinical implications and significance of sarcopenic obesity are not well understood. We systematically reviewed data on the prevalence and prognostic impact of sarcopenic obesity for patients with renal cell carcinoma, urothelial carcinoma and prostate cancer undergoing treatment.We searched EMBASE®, PubMed®/MEDLINE® and Scopus® for relevant original articles and abstracts published between January 2010 and February 2021. Primary outcomes were overall survival (OS), cancer-specific survival (CSS) and progression-free survival. The secondary outcome was the prevalence of sarcopenic obesity.A total of 15 studies comprising 3,866 patients were included. Of the 10 studies that evaluated survival outcomes, the association between sarcopenic obesity and survival was mixed. One of 10 studies showed a significant association of sarcopenic obesity with OS (HR 0.7, 95% CI 0.51-0.98; p=0.04). One additional study showed reported a trend for shorter OS (p=0.05) associated with sarcopenic obesity. Others reported that it is an adverse prognostic factor for CSS (HR 5.0, 95% CI 1.4-16.7; p=0.01). All other studies did not demonstrate that sarcopenic obesity was of prognostic relevance with regard to OS, CSS and progression-free survival. Overall, its mean prevalence was 27% (range 11-63).There is considerable heterogeneity in methods used to define sarcopenic obesity in the literature, and current data are limited. Future studies are needed to further understand the relationship of obesity and sarcopenia on the clinical trajectory of patients with urological cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|